BioInfect 2014 to Gather Life Science Professionals and Set the Global Antimicrobial Agenda
Bionow will be hosting the 2014 BioInfect Conference. A major one-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance, will take place at the Alderley Park Conference Centre, Cheshire on the 4 November 2014. The conference will again convene scientists, policy makers and government officials from across the world to drive forward and establish the global anti-microbial agenda.
The three main sessions that will be presented at the conference are “Progress: National and International Perspectives”, “Animal Health — the issues” and “Commercial Models.” In addition, there will be company technology showcases presenting leading innovation and development in this area. These include North West based Redx Anti-Infectives and Blueberry Therapeutics, QuantuMDx who are based in Newcastle and Discuva who are based in Cambridge.
Dr Geoff Davison, CEO of Bionow, commented: “To tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way to ensure that we have a health care system that can sustainably control and treat infections. BioInfect is a wonderful opportunity to bring together professionals from the life sciences industry, government and policy making bodies and explore the areas which can truly address this problem for mankind.”
BioInfect 2014 follows on from a very successful conference last year where Professor Dame Sally Davies, Chief Medical Officer, noted that "the golden age" of effective antibiotics has come to an end as no new class of drugs has been developing since 1987. She warned of the danger of going back to a pre-antibiotic era, where a simple infection could be a death sentence - a warning echoed by other speakers from around the globe. This year the Deputy Chief Medical Officer, Professor John Watson will inform delegates of the progress which the UK is making in the fight against this deadly threat.
BioInfect 2014, is hosted by Bionow and Redx Pharma, supported by AstraZeneca and sponsored by HGF Ltd, Boyd Consultants, Shore Capital and DWF LLP.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.